Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari
{"title":"PARP抑制后的铂化疗在HRR缺陷的转移性阉割耐药前列腺癌中的应用","authors":"Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari","doi":"10.1016/j.clgc.2024.102187","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.</p></span></li><li><span>•</span><span><p>A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.</p></span></li><li><span>•</span><span><p>In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.</p></span></li></ul></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer\",\"authors\":\"Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari\",\"doi\":\"10.1016/j.clgc.2024.102187\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>•</span><span><p>PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.</p></span></li><li><span>•</span><span><p>A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.</p></span></li><li><span>•</span><span><p>In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.</p></span></li></ul></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-08-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767324001587\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer
•
PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.
•
A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.
•
In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
